JP2002524532A5 - - Google Patents

Download PDF

Info

Publication number
JP2002524532A5
JP2002524532A5 JP2000569839A JP2000569839A JP2002524532A5 JP 2002524532 A5 JP2002524532 A5 JP 2002524532A5 JP 2000569839 A JP2000569839 A JP 2000569839A JP 2000569839 A JP2000569839 A JP 2000569839A JP 2002524532 A5 JP2002524532 A5 JP 2002524532A5
Authority
JP
Japan
Prior art keywords
vaccine
vaccine according
antigens
derived
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000569839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002524532A (ja
Filing date
Publication date
Priority claimed from GB9819898A external-priority patent/GB9819898D0/en
Application filed filed Critical
Publication of JP2002524532A publication Critical patent/JP2002524532A/ja
Publication of JP2002524532A5 publication Critical patent/JP2002524532A5/ja
Pending legal-status Critical Current

Links

JP2000569839A 1998-09-11 1999-09-08 新規ワクチンおよび使用方法 Pending JP2002524532A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9819898.9 1998-09-11
GB9819898A GB9819898D0 (en) 1998-09-11 1998-09-11 New vaccine and method of use
PCT/EP1999/006623 WO2000015255A1 (en) 1998-09-11 1999-09-08 Vaccine against sexually transmitted diseases

Publications (2)

Publication Number Publication Date
JP2002524532A JP2002524532A (ja) 2002-08-06
JP2002524532A5 true JP2002524532A5 (https=) 2006-10-19

Family

ID=10838766

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000569839A Pending JP2002524532A (ja) 1998-09-11 1999-09-08 新規ワクチンおよび使用方法

Country Status (28)

Country Link
EP (1) EP1109574B1 (https=)
JP (1) JP2002524532A (https=)
KR (1) KR100777896B1 (https=)
CN (2) CN1325311A (https=)
AR (1) AR021798A1 (https=)
AT (1) ATE392214T1 (https=)
AU (1) AU744989B2 (https=)
BR (1) BR9913630A (https=)
CA (1) CA2343399C (https=)
CO (1) CO5090882A1 (https=)
CY (1) CY1108147T1 (https=)
CZ (1) CZ302808B6 (https=)
DE (1) DE69938555T2 (https=)
DK (1) DK1109574T3 (https=)
ES (1) ES2304068T3 (https=)
GB (1) GB9819898D0 (https=)
HU (1) HUP0104297A3 (https=)
IL (1) IL141843A0 (https=)
MY (1) MY122216A (https=)
NO (1) NO329522B1 (https=)
NZ (1) NZ510425A (https=)
PL (1) PL199545B1 (https=)
PT (1) PT1109574E (https=)
SI (1) SI1109574T1 (https=)
TR (1) TR200100948T2 (https=)
TW (1) TWI225790B (https=)
WO (1) WO2000015255A1 (https=)
ZA (1) ZA200101987B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
US20090317421A1 (en) 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
CA2699513C (en) 2007-09-12 2018-03-13 Novartis Ag Gas57 mutant antigens and gas57 antibodies
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2011008400A2 (en) 2009-06-16 2011-01-20 Novartis Ag High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
AU2011237393B2 (en) 2010-04-08 2015-01-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education B-cell antigen presenting cell assay
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
CA2843854A1 (en) 2011-07-01 2013-01-10 The Regents Of The University Of California Herpes virus vaccine and methods of use
US11071745B2 (en) 2014-07-07 2021-07-27 Elian Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
JP7525976B2 (ja) * 2014-07-07 2024-07-31 エリアン リミテッド ライアビリティ カンパニー ウイルス予防治療方法及び曝露前予防キット
BR112018017141A2 (pt) 2016-02-22 2019-01-02 Boehringer Ingelheim Vetmedica Gmbh método para a imobilização de biomoléculas
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
ATE157882T1 (de) * 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines

Similar Documents

Publication Publication Date Title
JP2002524532A5 (https=)
CA2324289C (en) Combined vaccine compositions
KR100557665B1 (ko) 혼합 백신 조성물
JP4028593B2 (ja) 3−o脱アシル化モノホスホリルリピドa含有ワクチン組成物
US6692752B1 (en) Methods of treating human females susceptible to HSV infection
JP2003526673A5 (https=)
JP4694745B2 (ja) 新規組成物
CA2343399A1 (en) Method of vaccination against hsv in human females
Bernstein et al. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs
Stanberry et al. Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy
Stanberry Evaluation of herpes simplex virus vaccines in animals: the guinea pig vaginal model
CN1377274A (zh) 用母牛分枝杆菌治疗慢性病毒感染
Chomel et al. Prophylactic and therapeutic effects of murabutide in OF1 mice infected with influenza A and B viruses
AU2932502A (en) Vaccine against sexually transmitted diseases
MXPA01002532A (en) Vaccine against sexually transmitted diseases
Ogawa et al. Immunostimulatory activity of acyl derivatives of muramylpeptides orally administered with a protein antigen in liposomes to mice
Kong et al. Evaluation of natural and synthetic adjuvants in induction of autoimmune thyroiditis
Dayan et al. Genital herpes. An approach for general practitioners in Australia
MXPA00008817A (en) Combined vaccine compositions